13 Mar 2024 09:42
Hikma Pharmaceuticals PLC - EIP Vesting
LONDON, 13 March 2024: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 25 February 2022 under the 2014 Executive Incentive Plan ("EIP") Element B and 25 February 2021 under the EIP Element C.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Said Darwazah | |
2 | Reason for the notification | ||
a) | Position/status | Executive Chairman | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element B and EIP Element C. All Shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | EIP Award, Element B: 34,652 | ||
Nil | EIP Award, Element C: 19,830 | ||
d) | Aggregated information
| Price(s): nil Volume(s): 54,482 | |
e) | Date of the transaction | 12 March 2024 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Riad Mishlawi
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Riad Mishlawi | |
2 | Reason for the notification | ||
a) | Position/status | Chief Executive Officer | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element B and EIP Element C. All Shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | EIP Award, Element B: 22,099 | ||
Nil | EIP Award, Element C: 17,120 | ||
d) | Aggregated information
| Price(s): nil Volume(s): 39,219 | |
e) | Date of the transaction | 12 March 2024 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Mazen Darwazah
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Mazen Darwazah | |
2 | Reason for the notification | ||
a) | Position/status | Executive Vice Chairman | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element B and EIP Element C. All Shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | EIP Award, Element B: 26,812 | ||
Nil | EIP Award, Element C: 13,903 | ||
d) | Aggregated information
| Price(s): nil Volume(s): 40,715 | |
e) | Date of the transaction | 12 March 2024 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Khalid Nabilsi
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Khalid Nabilsi | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element B and EIP Element C. All Shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | EIP Award, Element B: 20,643 | ||
Nil | EIP Award, Element C: 13,927 | ||
d) | Aggregated information | Price(s): nil Volume(s): 34,570 | |
e) | Date of the transaction | 12 March 2024 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Brian Hoffmann
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Brian Hoffmann | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element B and EIP Element C. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | EIP Award, Element B: 14,663 | ||
Nil | EIP Award, Element C: 10,227 | ||
d) | Aggregated information | Price(s): nil Volume(s): 24,890 | |
e) | Date of the transaction | 12 March 2024 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares sold to cover tax following the vesting of conditional awards under the EIP Element B and EIP Element C. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
£18.942 | EIP Award, Element B: 5,471 | ||
£18.942 | EIP Award, Element C: 3,816 | ||
d) | Aggregated information | Price(s): £18.942 Volume(s): 9,287 Total(s): £175,916.51 | |
e) | Date of the transaction | 12 March 2024 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Susan Ringdal
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Susan Ringdal | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element B and EIP Element C. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | EIP Award, Element B: 11,072 | ||
Nil | EIP Award, Element C: 6,812 | ||
d) | Aggregated information | Price(s): nil Volume(s): 17,844 | |
e) | Date of the transaction | 12 March 2024 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares sold to cover tax following the vesting of conditional awards under the EIP Element B and EIP Element C. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
£18.942 | EIP Award, Element B: 5,109 | ||
£18.942 | EIP Award, Element C: 3,144 | ||
d) | Aggregated information | Price(s): £18.942 Volume(s): 8,253 Total(s): £156,330.24 | |
e) | Date of the transaction | 12 March 2024 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Hussein Arkhagha
1 | Details of the person discharging managerial responsibilities / person closely associated | ||
a) | Name | Hussein Arkhagha | |
2 | Reason for the notification | ||
a) | Position/status | PDMR | |
b) | Initial notification /Amendment | Initial notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Hikma Pharmaceuticals PLC | |
b) | LEI | 549300BNS685UXH4JI75 | |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | |
b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP Element B and EIP Element C. All Shares were retained. | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
Nil | EIP Award, Element B: 10,598 | ||
Nil | EIP Award, Element C: 5,245 | ||
d) | Aggregated information | Price(s): nil Volume(s): 15,843 | |
e) | Date of the transaction | 12 March 2024 | |
f) | Place of the transaction | London Stock Exchange (XLON) | |
Helen MiddlemistGroup Company Secretary
+44 (0)20 7399 2760
13 March 2024
Hikma Pharmaceuticals (HIK)